Health Costs

New and noteworthy

KFF/AP Survey Probes Rural Voters’ Increasing Anxieties About the Rising Cost of Living, Including Health Costs, Heading into the Midterm Elections

The KFF/AP Rural Voters Survey examines the views and political priorities of voters living in rural areas across the United States ahead of the 2026 midterm elections. The survey gauges rural voters’ top election issues, growing struggles with cost of living and health care costs, as well as views on the Trump administration’s health care policies.

Health System Tracker

How TrumpRx Brand-Name Drug Prices Compare

TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs.

The MIDTERMS

“...the search for a single top issue through polling questions — whether it’s health costs, or gas prices, or the cost of food — is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, ‘cost of living.’” — Drew Altman, KFF Founding President and CEO

Are Health Care Costs THE Top Issue for Voters?

In a new column, Dr. Drew Altman, Founding President and CEO, analyzes the polling on health costs as a voting issue and concludes that there is no one top voting issue. He writes: “I have come to the conclusion that the search for a single top issue through polling questions—whether it’s health costs, or gas prices, or the cost of food—is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, “cost of living.”

Stay informed.

Stay informed.

Filter

761-770 of 1,613 results

  • Web Briefing for Journalists: Marketplace Open Enrollment in the Trump Era

    Event Date:
    Event

    With the Trump administration’s announcements last week, the landscape around Affordable Care Act marketplaces and the open enrollment period beginning Nov. 1 continues to shift. Though the 2010 health law remains intact for now, consumers will see fundamental differences this year when it comes to signing up for 2018 marketplace plans. Premiums are increasing significantly in some states, though not all consumers will feel the impact. The enrollment period is shorter. Healthcare.gov will experience regular…

  • Prescription Drugs’ Sizable Share of Health Spending

    From Drew Altman

    In this column for The Wall Street Journal’s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it.

  • JAMA Forum: Surprise, Surprise

    Perspective

    Larry Levitt's February 2016 post explains how "surprise medical bills" -- unanticipated charges for out-of-network care - can happen. It describes some government approaches to the issue and outlines the challenges to protecting consumers. The post is now available at The JAMA Forum.

  • What New Data Tell Us About Doctor Choice

    News Release

    Is choice of doctors eroding? Drew Altman explores the rhetoric versus reality and why the issue resonates with Americans, in his latest column for The Wall Street Journal's Think Tank. All previous columns by Drew Altman are online.

  • 2023 Employer Health Benefits Survey

    Report

    This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, worker contributions, cost-sharing provisions, offer rates, and more. This year’s report also looks at how employers are addressing a growing need for mental health services.

  • How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices?

    Issue Brief

    A class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment. A new analysis compares list prices for semaglutide—including Ozempic, which has been approved in the U.S. for diabetes, and Wegovy, which has the same active ingredient and has been approved for weight…